Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “FLT3-ITD Mutation”

72 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 72 results

Testing effectiveness (Phase 2)Study completedNCT00553202
What this trial is testing

Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia

Who this might be right for
Leukemia
Children's Oncology Group 158
Not applicableUnknownNCT02156297
What this trial is testing

Sorafenib to Treat FLT3-ITD AML

Who this might be right for
Acute Myeloid LeukemiaFLT3-ITD Mutation
The First Affiliated Hospital of Soochow University 100
Large-scale testing (Phase 3)Study completedNCT02039726
What this trial is testing

(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive

Who this might be right for
AML
Daiichi Sankyo 367
Large-scale testing (Phase 3)Study completedNCT02668653
What this trial is testing

Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid LeukemiaLeukemia
Daiichi Sankyo 539
Early research (Phase 1)Study completedNCT01398501
What this trial is testing

Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant

Who this might be right for
Acute Myeloid Leukemia
Massachusetts General Hospital 22
Testing effectiveness (Phase 2)Looking for participantsNCT06262438
What this trial is testing

CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients

Who this might be right for
Acute Myeloid Leukemia in Children
Princess Maxima Center for Pediatric Oncology 60
Testing effectiveness (Phase 2)Study completedNCT02428543
What this trial is testing

Ponatinib for FLT3-ITD Acute Myelogenous Leukemia

Who this might be right for
Acute Myeloid Lukemia
Versailles Hospital 49
Testing effectiveness (Phase 2)Ended earlyNCT01028716
What this trial is testing

Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Who this might be right for
Acute Biphenotypic LeukemiaAcute Erythroid Leukemia in RemissionAcute Leukemia in Remission+27 more
Fred Hutchinson Cancer Center 46
Large-scale testing (Phase 3)Study completedNCT01371981
What this trial is testing

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaLeukemia CutisMyeloid Neoplasm+1 more
National Cancer Institute (NCI) 1,645
Testing effectiveness (Phase 2)Study completedNCT01565668
What this trial is testing

Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Leukemia, Myeloid, Acute
Daiichi Sankyo 76
Testing effectiveness (Phase 2)Study completedNCT02984995
What this trial is testing

Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation

Who this might be right for
Leukemia, Myeloid, Acute
Daiichi Sankyo Co., Ltd. 37
Testing effectiveness (Phase 2)Ended earlyNCT04240002
What this trial is testing

Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)
Astellas Pharma Global Development, Inc. 9
Large-scale testing (Phase 3)Not Yet RecruitingNCT05876832
What this trial is testing

XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)

Who this might be right for
Acute Myeloid Leukemia With FLT3/ITD Mutation
Shijiazhuang Yiling Pharmaceutical Co. Ltd 312
Large-scale testing (Phase 3)Looking for participantsNCT07463651
What this trial is testing

MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib

Who this might be right for
Acute Myeloid Leukemia (AML)FLT3-ITD MutationAllogeneic Hematopoietic Cell Transplantation (HCT)+3 more
The First Affiliated Hospital of Soochow University 594
Testing effectiveness (Phase 2)UnknownNCT03135054
What this trial is testing

Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD

Who this might be right for
AMLFLT3-ITD Mutation
The University of Hong Kong 40
Testing effectiveness (Phase 2)Study completedNCT01534260
What this trial is testing

Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype

Who this might be right for
Acute Myeloid Leukemia
Hamid Sayar 37
Testing effectiveness (Phase 2)Study completedNCT03836209
What this trial is testing

Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
PrECOG, LLC. 181
Testing effectiveness (Phase 2)Active Not RecruitingNCT03793478
What this trial is testing

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

Who this might be right for
Acute Myeloid Leukemia
Daiichi Sankyo 65
Testing effectiveness (Phase 2)Ended earlyNCT02634827
What this trial is testing

Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation

Who this might be right for
Acute Myeloid Leukemia With FLT3/ITD MutationAcute Myeloid Leukemia With Gene MutationsFLT3 Tyrosine Kinase Domain Point Mutation+2 more
Mayo Clinic 1
Early research (Phase 1)Looking for participantsNCT06222580
What this trial is testing

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

Who this might be right for
Acute Myeloid Leukemia With FLT3/ITD MutationAcute Myeloid Leukemia With KMT2A RearrangementAcute Myeloid Leukemia With NPM1 Mutation+2 more
Uma Borate 30
Next Page